Skip to main content
Premium Trial:

Request an Annual Quote

Bruker BioSciences Implements Post-Merger Consolidation

NEW YORK, Oct. 21 (GenomeWeb News) - Bruker BioSciences, which formed on July 1 through the merger of Bruker Daltonics and Bruker AXS, said yesterday that it is embarking upon a cost-cutting consolidation strategy that goes "beyond the original merger plan."

The restructuring, which has already been partially implemented and is expected to be finalized in the second quarter of 2004, includes the consolidation of the Bruker AXS x-ray systems production in Madison, Wis. The company will also outsource or transfer to its other production centers the manufacturing of certain technologies previously manufactured by Bruker-Nonius, a subsidiary of Bruker AXS located in Delft, The Netherlands. This business will now focus on applications for life science x-ray crystallography and structural proteomics, as well as on marketing and customer support, the company said. In addition, the Bruker Daltonics business will phase out manufacturing of substance detection products at its Faellanden, Switzerland, site by the end of the second quarter of 2004.

Bruker BioSciences said the consolidation plan should improve its operating performance by $2.5 million to $3.0 million annually pre-tax, beginning in the third quarter of 2004.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.